Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 1, 2018
Bispecific GD2 Antibody In Vivo Data to be Presented at ASH
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development ...
November 1, 2018
Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
MONT-SAINT-GUIBERT, Belgium, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
November 1, 2018
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
VANCOUVER, Nov. 1, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of ...
October 31, 2018
Orchard Therapeutics Announces Pricing of Initial Public Offering
BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious ...
October 31, 2018
CytoSorbents to Report Q3 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J., Oct. 31, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and ...
October 31, 2018
ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation ...
October 31, 2018
Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part ...
October 31, 2018
HTG Molecular Appoints Dr. Maureen T. Cronin as Chief Scientific Officer and Senior Vice President
TUCSON, Ariz., Oct. 31, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today ...
October 31, 2018
Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the Company will release its third quarter 2018 financial results and provide ...
October 31, 2018
CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
October 30, 2018
Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer ...
October 30, 2018
Prothena to Report Third Quarter 2018 Financial Results on November 6
DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and ...
October 30, 2018
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
October 30, 2018
Inventiva invited to present at Stifel 2018 Healthcare Conference in New York and at Jefferies 2018 London Healthcare Conference
Daix (France), October 30, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
October 30, 2018
OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 ...
October 30, 2018
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
NEC Corporation (NEC; TSE: 6701) and Transgene (TNG.PA) (Euronext Paris: TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration ...
October 30, 2018
InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing
JENA, Germany, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the ...
October 30, 2018
Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care
NASHUA, N.H., and MACON, Ga., Oct. 30, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, ...
October 30, 2018
Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
October 30, 2018
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study ...
Page 29 of 138